Alkermes is shifting its focus in neuroscience with ALKS 2680, which is expected to change the way narcolepsy is treated. This new approach could bring significant improvements for patients suffering from this sleep disorder.
ALKS has announced fourth-quarter 2024 results that exceeded expectations. There has been a year-over-year rise in net sales of their proprietary products.
Alkermes plc (NASDAQ:ALKS) will hold its Q4 2024 Earnings Conference Call on February 12, 2025, at 8:00 AM ET. The call will feature key company participants, including Sandra Coombs, Richard Pops, Blair Jackson, and Todd Nichols. Various conference call participants from different financial institutions will also be present.
Alkermes (ALKS) reported quarterly earnings of $1.04 per share, which is higher than the Zacks Consensus Estimate of $0.81 per share. This is an increase compared to earnings of $0.48 per share from the same period last year.
DUBLIN, Nov. 25, 2024 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) has announced that its management will take part in two investor conferences soon. The 7th Annual Evercore ISI HealthCONx Conference is scheduled for Tuesday, Dec. 3, 2024, at 10:25 a.m.
Alkermes has moved from earning money through royalties to selling its own products, thanks to the success of Lybalvi, Vivitrol, and Aristada. The company’s ALKS 2680, which is in Phase 2 trials for treating narcolepsy and hypersomnia, could be a game-changer in a market expected to reach $7.3 billion by 2032. With $908.9 million in available funds and a positive cash flow of $73.3 million in the third quarter, Alkermes is well-positioned to support its research and development as well as its operations.
ALKS has announced that its results for the third quarter of 2024 were not as strong as anticipated. However, the net sales of its own products have risen compared to the previous year.
Alkermes plc (NASDAQ:ALKS) will hold its Q3 2024 Earnings Conference Call on October 24, 2024, at 8:00 AM ET. The call will feature company representatives including Sandra Coombs, Richard Pops, Todd Nichols, and Blair Jackson. Various analysts from firms like TD Cowen, Evercore, and JPMorgan will also participate in the call.
Alkermes (ALKS) reported quarterly earnings of $0.73 per share, which is lower than the Zacks Consensus Estimate of $0.78 per share. This is an increase from the earnings of $0.64 per share from the same period last year.
The main figures for Alkermes (ALKS) provide an overview of the company's performance for the quarter that ended in September 2024. However, it could be useful to look at some of its important metrics in relation to Wall Street predictions and the results from the same period last year.